Aureka Biotechnologies has raised $100.0M in a Series B round, a sizable bet on its AI-driven approach to immunotherapeutic discovery. The financing was led by Granite Asia, with participation from HighLight Capital (HLC), MPCi, and NRL Capital.
The startup’s pitch is that it can speed up drug development by merging microfluidics, synthetic biology, and AI into a single platform, letting partners move from concept to clinic faster than traditional methods. The fresh capital gives Aureka runway to push that platform further, though the company hasn't detailed specific allocation plans.
